BPDCN is an aggressive hematologic malignancy with a historically poor prognosis VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around ...

BPDCN is an aggressive hematologic malignancy with a historically poor prognosis VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools ...

BPDCN is an aggressive hematologic malignancy with a historically poor prognosis VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools ...

FLORENCE, Italy and NEW YORK, March 20, 2025 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc ...

The AI model is now live within VisualDx. Menarini Industrie Farmaceutiche Riunite Logo (PRNewsfoto/Menarini Industrie Farmaceutiche Riunite) VisualDx is a physician-led company committed to ...